



Save License



Dec 1, 2008 By: Ron Feemster PHARMACEUTICAL EXECUTIVE

Meningitis vaccines

A new Prevnar, plus new vaccines from Novartis and GSK



Established meningitis vaccines may lose market share to their successors beginning next year, when a fresh crop of multivalent vaccines is expected to hit the market.

Email Print

Candidates by Wyeth and Novartis are expected to become at least \$2 billion opportunities, according to Datamonitor's Holger Rovini.

Wyeth's **Prevnar** family of vaccines protect against pneumococcal serotypes that cause a variety of infections including blood infections and



MOST POPULAR ARTICLES

Should The US Gamble With Risk Sharing?
Pharma And Social Media: Ready To Make Nice?
Get Back In The Box!
12th Annual Pharm Exec 50

Innovation: Why Is Pharma Scared To Death?

MORE ARTICLES

WEBCASTS

FREE REGISTRATION

meningitis. The original Prevnar worked against seven serotypes. The new version, **PNCRM13**, also known as Prevnar 13v, targets those seven plus six more, including 19A, which is especially important in Asia. An additional indication is being sought for vaccinating the elderly. Rovini cited data that indicate vaccinating the very young can reduce the incidence of pneumococcal infections in the elderly, because vaccinated children do not infect their caregivers.

Synflorix, a 10-valent vaccine, excludes serotype 19A but adds non-typeable Haemophilus influenzae. The GSK drug could reach peak sales of \$600–700 million.

Menveo could reap upwards of \$2 billion for Novartis, according to Datamonitor. It competes with Sanofi-Pasteur's Menactra. Rovini notes that clinical data released by Novartis make Menveo appear superior, but the endpoints chosen may not prove any advantage over Menactra in terms of real-world benefits.

Pain

Breakthrough NSAIDS

PIlls can be slow and relatively ineffective (to say nothing of addictive), and self-injection is a problem for many patients. As a result, too many post-operative patients spend extra days in the hospital. Rox 888, Roxro's new nasally delivered formulation of the NSAID keterolac solves both of those problems. Rox 888 is fast acting and has proven as effective as intramuscular injections of keterolac in the control of abdominal and orthopedic post-surgical pain.

DRUG NAME	Rox 888
DRUGMAKER	Roxro Pharma
PHASE	Phase III
DRUG NAME	Naproxcinod
DRUGMAKER	NiCox
PHASE	Phase III




Holger Rovini

"This is a drug that can be easily administered in a home environment," says Neil Singla, MD, of Lotus Clinical Research in Pasadena, CA. "That's a huge advantage."

Meanwhile NiCox, a French company with an attractive nitric oxide—contributing technology has received positive Phase III results on its **naproxcinod**—which hit all its end points without detrimental effects to patient blood pressure. At a time when chronic pain meds are increasingly under fire for cardiac side effects, naproxcinod and the class of drugs coming up behind it could become major

players.





ABOUT THE AUTHOR
Ron Feemster
Articles by Ron Feemster

POST A COMMENT

Please Complete The Form Below To Post Your Comment.

Bold = Required

Email Address

Display Name

City

State

Supply Chain Strategy: Managing risk and opportunity in a changing global landscape Sponsored By PricewaterhouseCoopers LLP

Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)

Sponsored By PricewaterhouseCoopers LLP

Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost Sponsored By ClearTrial

ARCHIVED WEBCASTS







Featured Q&A- Clinical Portals: Balancing Sponsor and Site Perspectives A wrapup of the discussions at CBI's 3rd Summit on Clinical Trial Investigator Portals

INTRALINKS



Meet 2011's Emerging Pharma Leaders VIEW PDF: Can these 30 trendsetters build competitive scale from scarcity?

PODCAST: Listen to audio interviews with 7 of the Emerging Pharma Leaders sponsored by:





2011 Pharm Exec 50 Ranks the world's largest pharmaceutical companies by global sales of prescription drugs. sponsored by:





Pharma Country Reports
Market reports on pharma
developments worldwide
sponsored by:



Featured Jobs

Senior Manager, Positioning Strategy
Brand Engineers, LLC - Teaneck, New Jersey

Sr. Research Program Coordinator Johns Hopkins University - Baltimore, Maryland

More Jobs

